肝移植患者外周血辅助性T17细胞的变化及意义

李平; 樊华; 寇建涛; 韩东冬; 朱继巧; 贺强

doi:10.3969/j.issn.1674-7445.2014.04.005

肝移植患者外周血辅助性T17细胞的变化及意义

doi: 10.3969/j.issn.1674-7445.2014.04.005

100020 北京, 首都医科大学附属北京朝阳医院肝胆胰脾外科

基金项目:

北京市自然科学基金 7123212

详细信息

通讯作者:
贺强,Email:heqiang349@sina.com

中图分类号: R617
计量
- 文章访问数: 104
- HTML全文浏览量: 85
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2014-03-10
- 网络出版日期: 2021-01-19
- 刊出日期: 2014-07-15

Variation and significance of T helper 17 cells in peripheral blood in patients after liver transplantation

Department of Hepatobiliary and Pancreas-Spleen Surgery, Affiliated Beijing Chaoyang Hospital, Capital Medical University, 100020 Beijing, China

摘要

摘要: 目的探讨肝移植术后患者外周血辅助性T(Th)17细胞(CD4⁺IL-17⁺T淋巴细胞)与急性排斥反应的关系。方法本文研究对象为2008年6月至2012年12月在首都医科大学附属北京朝阳医院肝胆胰脾外科因良性终末期肝病行原位肝移植术的76例患者。根据患者术后有否发生急性排斥反应,分为排斥组(17例)和非排斥组(59例)。所有患者均按常规定期随访。记录患者排斥反应发生情况及治疗经过。排斥组患者发生急性排斥反应时给予肝穿刺活组织检查确定排斥反应严重程度。所有患者分别于肝移植术前、出院后1年内定期(间隔3~6个月)、或急性排斥反应治疗前和缓解后(3~6个月),检测外周血CD4⁺IL-17⁺T淋巴细胞占CD4⁺T淋巴细胞百分比(CD4⁺IL-17⁺T%)。比较两组患者各时间点的CD4⁺IL-17⁺T%。分析CD4⁺IL-17⁺T%与排斥活动指数(RAI)、免疫抑制剂血药浓度的相关性。结果急性排斥反应发生在术后0.7~12.0个月,中位数2.5个月。肝移植术后,与非排斥组比较,排斥组患者CD4⁺IL-17⁺T%明显升高[(1.79±0.44)%比(2.56±0.43)%,P<0.001]。排斥组患者发生急性排斥反应时,CD4⁺IL-17⁺T%均较未发生急性排斥反应时明显升高[(2.56±0.43)%比(1.50±0.25)%,P<0.001)]。非排斥组患者不同时间点的CD4⁺IL-17⁺T%变化不明显(P>0.05)。排斥组患者发生急性排斥反应时的CD4⁺IL-17⁺T%与RAI呈正相关(r=0.72,P=0.001)。排斥组和非排斥组患者他克莫司、环孢素血药浓度与CD4⁺IL-17⁺T%无明显相关性(r=0.21,-0.13;均为P>0.05)。结论外周血CD4⁺IL-17⁺T%可作为诊断和评估肝移植术后急性排斥反应严重程度的监测指标,外周血CD4⁺IL-17⁺T%升高提示急性排斥反应严重。
- 肝移植 /
- 急性排斥反应 /
- 辅助性T17细胞 /
- 白细胞介素17
Abstract: Objective To study the relationship between T helper (Th)17 cell [CD4⁺ interleukin (IL)-17⁺T lymphocytes] in peripheral blood and acute rejection in patients after liver transplantation. Methods A total of 76 patients receiving orthotopic liver transplantation (OLT) for benign end-stage liver diseases in Department of Hepatobiliary and Pancreas-Spleen Surgery, Affiliated Beijing Chaoyang Hospital of Capital Medical University from June 2008 to December 2012 were included in this study. According to whether the acute rejection occurred after operation, the patients were divided into rejection group (n=17) and non-rejection group (n=59). All the patients were followed up regularly by routine. The incidence of rejection and the treatment of patients were recorded. Patients in the rejection group received liver biopsy when suffered acute rejection to decide the severity. The percentage of CD4⁺IL-17⁺T lymphocytes to CD4⁺T lymphocytes (CD4⁺IL-17⁺T%) in peripheral blood in all patients was measured at different time points: pre-OLT, at regular intervals (3-6 months) within 1 year after hospital discharge or before the treatment of acute rejection and after the remission (3-6 months). The CD4⁺IL-17⁺T% of every time point were compared between two groups. The correlations of CD4⁺IL-17⁺T% with the rejection activity index (RAI), blood concentration of immunosuppressor were analyzed. Results The acute rejection occurred in 0.7-12.0 (median: 2.5)months after OLT. The CD4⁺IL-17⁺T% in the rejection group increased significantly compared with that in the non-rejection group after OLT [(2.56±0.43)% vs.(1.79±0.44)%, P<0.001]. In the rejection group, the CD4⁺IL-17⁺T% increased significantly when acute rejection occurred compared with that when acute rejection had not occurred [(2.56±0.43)% vs.(1.50±0.25)%,P<0.001)]. The variation of CD4⁺IL-17⁺T% was not obvious at different time points in non-rejection group(P>0.05). The CD4⁺IL-17⁺T% was positively correlated with RAI when acute rejection occurred in the rejection group (r=0.72,P=0.001). The blood concentration of tacrolimus, cyclosporin in rejection and non-rejection group were not correlated with CD4⁺IL-17⁺T% (r=0.21,-0.13; both in P>0.05). Conclusions CD4⁺IL-17⁺T%in peripheral blood can be used as a monitoring index for deciding and assessing severity of acute rejection after OLT. The increase of CD4⁺IL-17⁺T% in peripheral blood indicates a severe acute rejection.
- Liver transplantation /
- Acute rejection /
- T helper 17 cell /
- Interleukin-17

HTML全文

图 1 排斥组某患者在发生和未发生急性排斥反应时外周血CD4⁺IL-17⁺T淋巴细胞流式图

Figure 1. Flow cytometry of CD4⁺IL-17⁺ T lymphocytes in peripheral blood of a patient in rejection group before and during acute rejection

下载: 全尺寸图片幻灯片

图 2 排斥组患者CD4⁺IL-17⁺ T%与排斥活动指数相关性分析

Figure 2. Correlation analysis between the percentage of CD4⁺IL-17⁺ T lymphocytes and the rejection activity index of patients in rejection group

下载: 全尺寸图片幻灯片

参考文献(21)

[1]	贾俊君,王丽,张静,等.肝移植后长期生存受者外周血淋巴细胞亚群及细胞因子分析[J].中华器官移植杂志,2013,34(11):666-670. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZJKX201311007084.htm Jia JJ, Wang L, Zhang J, et al. Analysis on lymphocytes subgroup and cytokines level of the long-term survival patients after OLT[J]. Chin J Organ Transplant,2013,34(11):666-670. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-ZJKX201311007084.htm
[2]	Lafdil F, Miller AM, Ki SH, et al. Th17 cells and their associated cytokines in liver diseases[J]. Cell Mol Immunol,2010,7(4):250-254. doi: 10.1038/cmi.2010.5
[3]	Brembilla NC, Chizzolini C. T cell abnormalities in systemic sclerosis with a focus on Th17 cells[J]. Eur Cytokine Netw,2012,23(4):128-139. http://cn.bing.com/academic/profile?id=274383712&encoded=0&v=paper_preview&mkt=zh-cn
[4]	Niu X, He D, Zhang X, et al. IL-21 regulates Th17 cells in rheumatoid arthritis[J]. Hum Immunol,2010,71(4):334-341. doi: 10.1016/j.humimm.2010.01.010
[5]	Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation[J]. Liver Transpl,2009,15(11):S1-S34. doi: 10.1002/lt.v15:11
[6]	Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy[J]. J Exp Med,2008,205(13):3133-3144. doi: 10.1084/jem.20081937
[7]	Wang G, Zhong A, Wang S, et al. Retinoic acid attenuates acute heart rejection by increasing regulatory T cell and repressing differentiation of Th17 cell in the presence of TGF-β[J]. Transpl Int,2010,23(10):986-997. doi: 10.1111/j.1432-2277.2010.01080.x
[8]	Fábrega E, López-Hoyos M, San Segundo D, et al. Effect of immunosuppressant blood levels on serum concentration of interleukin -17 and -23 in stable liver transplant recipients[J]. Transplant Proc,2009,41(3):1025-1027. doi: 10.1016/j.transproceed.2009.01.046
[9]	Benghiat FS, Charbonnier LM, Vokaer B, et al. Interleukin 17-producing T helper cells in alloimmunity[J]. Transplant Rev,2009,23(1):11-18. doi: 10.1016/j.trre.2008.08.007
[10]	Gorbacheva V, Fan R, Li X, et al. Interleukin-17 promotes early allograft inflammation[J]. Am J Pathol,2010,177(3):1265-1273. doi: 10.2353/ajpath.2010.091106
[11]	Wang S, Li J, Xie A, et al. Dynamic changes in Th1, Th17, and FoxP3⁺ T cells in patients with acute cellular rejection after cardiac transplantation[J]. Clin Transplant,2011,25(2):E177-E186. doi: 10.1111/ctr.2011.25.issue-2
[12]	Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al. The role of interleukin-17 during acute rejection after lung transplantation[J]. Eur Respir J,2006,27(4):779-787. doi: 10.1183/09031936.06.00019405
[13]	Fábrega E, López-Hoyos M, San Segundo D, et al. Effect of immunosuppressant blood levels on serum concentration of interleukin -17 and -23 in stable liver transplant recipients[J]. Transplant Proc,2009,41(3):1025-1027. doi: 10.1016/j.transproceed.2009.01.046
[14]	Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells[J]. Immunol Res,2008,41(2):87-102. doi: 10.1007/s12026-007-8014-9
[15]	Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 cells[J]. Annu Rev Immunol,2009,27:485-517. doi: 10.1146/annurev.immunol.021908.132710
[16]	Volpe E, Touzot M, Servant N, et al. Multiparametric analysis of cytokine-driven human Th17 differentiation reveals a differential regulation of IL-17 and IL-22 production[J]. Blood,2009,114(17):3610-3614. doi: 10.1182/blood-2009-05-223768
[17]	Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17(Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease[J]. Clin Exp Immunol,2007,148(1):32-46. doi: 10.1111/cei.2007.148.issue-1
[18]	Hanidziar D, Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance[J]. Curr Opin Organ Transplant,2010,15(4):411-415. doi: 10.1097/MOT.0b013e32833b7929
[19]	Chen H, Wang W, Xie H, et al. A pathogenic role of IL-17 at the early stage of corneal allograft rejection[J]. Transpl Immunol,2009,21(3):155-161. doi: 10.1016/j.trim.2009.03.006
[20]	Zhang C, Zhang J, Yang B, et al. Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis[J]. Cytokine,2008,42(3):345-352. doi: 10.1016/j.cyto.2008.03.006
[21]	Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4⁺ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol,2005,6(11):1123-1132. doi: 10.1038/ni1254